Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study

Abstract Introduction Clinical trials have demonstrated prolonged survival associated with niraparib first-line maintenance (1LM) therapy, compared with placebo, for patients with ovarian cancer (OC). However, data are limited on real-world 1LM niraparib monotherapy use, particularly as switch 1LM,...

Полное описание

Библиографические подробности

Главные авторы:	Bobbie Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M. Schilder, Jean A. Hurteau, Amanda Golembesky
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Adis, Springer Healthcare 2024-07-01
Серии:	Oncology and Therapy
Предметы:	First-line maintenance therapy Niraparib Ovarian cancer Real-world Switch maintenance Time to next treatment
Online-ссылка:	https://doi.org/10.1007/s40487-024-00281-8
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!